|
CV Information
 PROFESOR DR. LEE YEONG YEH
| |
|---|---|
|
Grant's Name,"Project's Title" (Research Period)(Role)[Sponsorship]
| |
| 1 | EXTERNAL AGENCY (INTERNATIONAL), "MORINAGA-USM GUT HEALTH & MICROBIOTA PROJECT: ROLE OF BIFIDOBACTERIUM INFANTIS M63 IN RESTORING GUT MICROBIOTA BALANCE OF IRRITABLE BOWEL SYNDROME (PROJECT 1) AND TYPE-2 DIABETES MELLITUS (PROJECT 2)" (01.10.2017 - 30.09.2020) (Principal) [ MORINAGA MILK INDUSTRY CO. LTD. ] - Source: eR&I |
| 2 | , "A PHASE 2B, MULTICENTER, DOUBLE-BLIND, ACTIVE-CONTROLLED, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DIFFERENT COMBINATION REGIMENS INCLUDING JNJ-73763989 AND/OR JNJ-56136379 FOR THE TREATMENT F CHRONIC HEPATITIS B VIRUS INFECTION" (13.11.2019 - 13.11.2019) [ Johnson & Johnson ] - Source: HCMSv3 |
| 3 | , "LILLY UC PROGRAM PROTOCOLS 16T-MC-AMAN & 16T-MC-AMBG" (28.03.2018 - 29.02.2020) [ Lilly & IVQIA ] - Source: HCMSv3 |
| 4 | , "ALLERGAN RELAMORELIN PROGRAM RLM-MD-01, RLM-MD-03 AND RLM-MD-04" (13.10.2017 - 30.09.2020) [ Allergan ] - Source: HCMSv3 |
| 5 | , "TAK-438_305 EFFICACY AND SAFETY OF VONOPRAZAN COMPARED TO LANSOPRAZOLE IN THE MAINTENANCE TREATMENT OF EROSIVE ESOPHAGITIS" (06.03.2017 - 30.09.2018) [ Takeda Pharmaceuticals ] - Source: HCMSv3 |
| 6 | , "AN OPEN-LABEL RANDOMIZED-CONTROLLED STUDY WITH THE 48-H BRAVO® CAPSULE AND PH-IMPEDANCE MONITORING TO ASSESS THE EFFECTIVENESS OF POSTPRANDIAL AND NIGHT-TIME ACID REFLUX SUPPRESSION WITH ALGINATE-ANTACID PREPARATION IN OBESE ASYMPTOMATIC PARTICIPANT" (15.12.2015 - 14.12.2016) (03) [ Reckitt Beckinser ] - Source: HCMSv3 |
| 7 | , "TAK-438_303 EFFICACY AND SAFETY OF ORAL ONCE-DAILY VONOPRAZAN (TAK-438) IN PARTICIPANTS WITH EROSIVE ESOPHAGITIS" (02.03.2015 - 01.04.2016) (06) [ Takeda Pharmaceuticals ] - Source: HCMSv3 |
| 8 | , "GEMINI: C13006-A, C13007-A AND C13008-A: PHASE 3 MULTICENTER STUDY OF THE INDUCTION AND MAINTENANCE OF CLINICAL RESPONSE AND REMISSION BY MLN0002 IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS AND CROHN'S DISEASE AND LONG TERM SAFETY" (02.06.2008 - 23.09.2009) (06) [ Takeda Millenium ] - Source: HCMSv3 |
| 9 | , "VERMEER S308.3.003 STUDY: A MULTICENTER, RANDOMIZED, DOUBLE BLIND, PARALLEL-GROUP PLACEBO AND PRAMIPEXOLE CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF SLV308 MONOTHERAPY IN THE TREATMENT OF PATIENTS WITH EARLY STAGE PARKINSON'S DISEASE" (04.12.2006 - 26.06.2008) (03) [ Solvay Pharmaceuticals ] - Source: HCMSv3 |
| 10 | , "REFLECT-3 STUDY (AVA102670): A 54 WEEK, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFECTS OF ROSIGLITAZONE (EXTENDED RELEASE TABLETS) AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS ON COGNITION AN" (01.11.2006 - 01.11.2006) (06) [ GlaxoSmithKline ] - Source: HCMSv3 |
| 11 | , "LAM100036 STUDY:A MULTICENTER, DOUBLE BLIND, RANDOMIZED, PARALLEL GROUP EVALUATION OF LAMICTAL EXTENDED RELEASE ADJUNCTIVE THERAPY IN SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES" (01.11.2006 - 01.11.2006) (03) [ GlaxoSmithKline ] - Source: HCMSv3 |
| 12 | , "ASCEND STUDY:A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFECT OF THE ENDOTHELIN RECEPTOR ANTAGONIST AVOSENTAN ON TIME TO DOUBLING OF SERUM CREATININE, END STAGE RENAL DISEASE OR DEATH IN PATIENTS WITH TYPE 2 D" (01.08.2006 - 01.08.2006) (06) [ Speedel Pharma Ltd ] - Source: HCMSv3 |
| 13 | , "STROKE OBSERVATIONAL PROGRAM IN ASIA (STROKOP-ASIA)" (01.03.2006 - 01.03.2006) (03) [ Sanofi-Aventis ] - Source: HCMSv3 |
| 14 | , "EMD2003 STUDY: A PROSPECTIVE OBSERVATIONAL STUDY OF ACUTE MAJOR ORGAN SYSTEM FAILURE IN SEPTIC PATIENTS" (04.08.2003 - 27.08.2004) (06) [ GlaxoSmithKline ] - Source: HCMSv3 |